LGDN:FRA
Ligand Pharmaceuticals Inc
€188.00
arrow_downward
-2.08%(-4.00) 1 天
4月30日, GMT+2 22:00:00 · EUR
search
所有股票代码
1 天
5 天
1 个月
6 个月
年初至今
1 年
5 年
最大
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 LGDN 生成关键数据洞见…
开盘价
€190.00
最高价
€190.00
最低价
€188.00
市值
四五.五八亿
平均成交量
三.〇〇
成交量
〇.〇〇
52 周最高价
€204.00
52 周最低价
€87.00
员工人数
四七
新闻报道
来自全网
资料
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
Ligand Pharmaceuticals Inc简介